未登录

M

Marie-Laure Névoret

National Jewish Health

H指数:6

被引数:848

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Psychometric validation of the PROMIS Fatigue-Short Form 7a in adults with newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung disease: the ARISE and ENCORE studies

PROMIS疲劳简表7a在 newly diagnosed 或 recurrent Mycobacterium avium complex (MAC) 肺病患者中的心理测量学验证：ARISE 和 ENCORE 研究

JOURNAL OF PATIENT-REPORTED OUTCOMES

IF2.9

2025-10-160

OA

Lived Experience of Patients and Caregivers in Rare Genetic Neurological Gene Therapy Clinical Trials in Children

PEDIATRIC NEUROLOGY

IF2.1

2025-02-010

PRE

Correlation between culture conversion and Quality of Life-Bronchiectasis Respiratory Domain (QOL-B RD) in adults with Mycobacterium avium complex lung disease (MACLD): The ARISE Study

EUROPEAN RESPIRATORY JOURNAL

IF21

2024-10-300

PRE

RGX-111 gene therapy for the treatment of severe mucopolysaccharidosis type I (MPS I): Interim analysis of data from the first in-human study

MOLECULAR GENETICS AND METABOLISM

IF3.5

2022-02-010

PRE

Beyond the normative data: Understanding the Mullen Scales of Early Learning (MSEL)

MOLECULAR GENETICS AND METABOLISM

IF3.5

2022-02-012

PRE

Beyond the normative data: Understanding the Bayley Scales of Infant Development version 3 (BSID-III)

MOLECULAR GENETICS AND METABOLISM

IF3.5

2022-02-010

PRE

Identification of a biomarker that differentiates neuronopathic forms of MPS I and MPS II

MOLECULAR GENETICS AND METABOLISM

IF3.5

2022-02-012

PRE

RGX-121 gene therapy for the treatment of severe mucopolysaccharidosis type II (MPS II): Interim analysis of data from the first in-human study

MOLECULAR GENETICS AND METABOLISM

IF3.5

2022-02-011

PRE

The expanded neuronal ceroid lipofuscinosis 2 (CLN2) clinical rating scale for motor and language function: Development and inter-rater reliability

MOLECULAR GENETICS AND METABOLISM

IF3.5

2022-02-010

PRE

First in-human intracisternal dosing of RGX-111 (adeno-associated virus 9/human α-L-iduronidase) for a 20-month-old child with mucopolysaccharidosis type I (MPS I): 1 year follow-up

MOLECULAR GENETICS AND METABOLISM

IF3.5

2021-02-010

PREAI

Intracisternal administration of AAV9 gene therapies to target the central nervous system

MOLECULAR GENETICS AND METABOLISM

IF3.5

2021-02-010

PREAI

Characterizing expressive language skills in children with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2): The caregiver perspective

MOLECULAR GENETICS AND METABOLISM

IF3.5

2021-02-010

PREAI

RGX-121 gene therapy for severe mucopolysaccharidosis type II (MPS II): A clinical program to address central nervous system manifestations

MOLECULAR GENETICS AND METABOLISM

IF3.5

2021-02-012

PREAI

RGX-121 gene therapy for severe mucopolysaccharidosis type II (MPS II): Interim results of an ongoing first in human trial

MOLECULAR GENETICS AND METABOLISM

IF3.5

2021-02-012

PREAI

Electrochemical skin conductance is sensitive and has clinical utility in patients with untreated or poorly controlled diabetes

BIOMEDICAL ENGINEERING LETTERS

IF2.8

2019-08-291

OAAI

Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events

FRONTIERS IN NEUROSCIENCE

IF3.2

2018-08-2795

OAAI

Diagnostic accuracy of neuropathy tests in obese population remains elusive

CLINICAL NEUROPHYSIOLOGY

IF3.6

2018-07-011

PREAI

Accuracy of a Rapid and Non-Invasive Method for the Assessment of Small Fiber Neuropathy Based on Measurement of Electrochemical Skin Conductances

FRONTIERS IN ENDOCRINOLOGY

IF4.6

2016-02-2924

OAAI

The new age of sudomotor function testing: a sensitive and specific biomarker for diagnosis, estimation of severity, monitoring progression, and regression in response to intervention

FRONTIERS IN ENDOCRINOLOGY

IF4.6

2015-06-1195

OAAI